id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-290960-0kdv91j0	Rojas-Marte, G	Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study	2020-06-19		.txt	text/plain	2778	184	52	METHODS: We conducted a retrospective, case–control, single-center study in patients with severe to critical COVID-19 disease treated with tocilizumab. CONCLUSION: Our study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease who received tocilizumab. 9, 10 Studies have reported that patients with severe COVID-19 disease have experienced rapid resolution of fever and improvement in oxygenation after treatment with tocilizumab. No clinical study has reported the use of tocilizumab among hospitalized patients with severe COVID-19 infection in the USA. A control group of 97 patients with PCR-confirmed COVID-19 disease who had not received tocilizumab was included. We analyzed the clinical characteristics and outcomes of 96 patients with severe to critical COVID-19 disease who received a single dose of the IL-6 inhibitor tocilizumab as part of their treatment. Our study showed a non-significant trend toward lower mortality in patients with severe to critical COVID-19 disease treated with tocilizumab.	./cache/cord-290960-0kdv91j0.txt	./txt/cord-290960-0kdv91j0.txt